GeneDx CEO Katherine Stueland Named to TIME100 Health List
Event summary
- GeneDx CEO Katherine Stueland named to TIME100 Health 2026 list.
- Recognition underscores growing global acknowledgment of rare disease as a public health priority.
- GeneDx Infinity™ dataset and exome/genome testing receive FDA Breakthrough Device Designation.
- American Academy of Pediatrics updates clinical guidance to recommend GeneDx’s tests for children with developmental delays.
The big picture
GeneDx’s inclusion in the TIME100 Health list highlights the increasing importance of genomics in modern medicine. The company’s leadership in rare disease diagnostics, supported by its extensive genomic dataset and strategic partnerships, positions it at the forefront of precision medicine. The recognition comes amid growing regulatory validation and clinical adoption, signaling a broader shift towards proactive, population-scale health.
What we're watching
- Regulatory Validation
- How FDA Breakthrough Device Designation will accelerate adoption of GeneDx’s exome and genome testing.
- Market Expansion
- Whether GeneDx can sustain its growth through public-private initiatives like the GUARDIAN study and BEACONS program.
- Clinical Impact
- The pace at which AAP’s updated clinical guidance will drive earlier diagnosis and improved outcomes for children with rare diseases.
Our editorial coverage:
Related topics